Strides Pharma Financials
| STAR Stock | 877.80 7.20 0.81% |
Operating Margin | PE Ratio 20.1608 | Profit Margin | Payout Ratio 0.0568 | EPS Estimate Current Year 36 |
Strides | Select Account or Indicator |
Please note, the imprecision that can be found in Strides Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Strides Pharma Science. Check Strides Pharma's Beneish M Score to see the likelihood of Strides Pharma's management manipulating its earnings.
Strides Pharma Stock Summary
Strides Pharma competes with ROUTE MOBILE, Mangalore Chemicals, Rashtriya Chemicals, Pritish Nandy, and FCS Software. Strides Pharma is entity of India. It is traded as Stock on NSE exchange.| Foreign Associate | USA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | India Stock View All |
| Exchange | National Stock Exchange of India |
| ISIN | INE939A01011 |
| Business Address | Strides House, Bengaluru, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.strides.com |
| Phone | 91 80 6784 0000 |
You should never invest in Strides Pharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Strides Stock, because this is throwing your money away. Analyzing the key information contained in Strides Pharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Strides Pharma Key Financial Ratios
There are many critical financial ratios that Strides Pharma's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Strides Pharma Science reports annually and quarterly.| Revenue | 46.24 B | ||||
| Gross Profit | 24.37 B | ||||
| EBITDA | 8.62 B | ||||
| Net Income | 35.93 B | ||||
| Total Asset | 60.49 B |
Strides Pharma Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 70.2B | 69.8B | 66.4B | 58.4B | 60.5B | 51.7B | |
| Other Current Liab | 2.9B | 2.9B | 2.6B | 1.9B | 3.0B | 1.7B | |
| Net Debt | 22.2B | 28.5B | 27.3B | 23.6B | 17.4B | 19.4B | |
| Accounts Payable | 11.3B | 10.7B | 9.8B | 8.5B | 10.3B | 6.6B | |
| Cash | 1.3B | 1.7B | 3.0B | 1.6B | 1.4B | 2.1B | |
| Good Will | 4.8B | 4.9B | 5.1B | 5.3B | 5.5B | 7.7B | |
| Inventory | 12.0B | 11.7B | 11.5B | 11.3B | 12.8B | 13.4B | |
| Other Current Assets | 13.4B | 20.1B | 4.4B | 4.1B | 4.1B | 6.0B | |
| Total Liab | 42.0B | 45.9B | 44.7B | 37.7B | 34.6B | 32.8B | |
| Total Current Assets | 28.2B | 33.6B | 32.4B | 29.7B | 31.0B | 22.2B | |
| Intangible Assets | 6.2B | 6.2B | 5.6B | 5.3B | 5.7B | 5.9B | |
| Common Stock | 896.8M | 897.9M | 903.0M | 919M | 921.6M | 869.6M | |
| Short Term Debt | 12.6B | 20.0B | 16.9B | 17.7B | 12.6B | 12.1B | |
| Retained Earnings | 4.8B | 23.1M | (2.0B) | (2.8B) | (2.6B) | (2.4B) | |
| Other Liab | 7.1B | 1.5B | 3.7B | 1.6B | 1.8B | 3.4B | |
| Net Tangible Assets | (2.4B) | 15.5B | 16.8B | 12.5B | 14.4B | 7.9B | |
| Other Assets | 9.1B | 9.9B | 4.5B | 5.0B | 5.8B | 4.8B | |
| Long Term Debt | 8.8B | 8.4B | 11.4B | 6.7B | 5.7B | 8.6B | |
| Short Long Term Debt | 10.2B | 19.6B | 16.3B | 17.4B | 12.2B | 13.4B | |
| Net Invested Capital | 46.8B | 51.5B | 49.9B | 45.4B | 43.5B | 39.0B | |
| Net Working Capital | 788.9M | (498.4M) | 2.5B | 897.4M | 5.1B | 5.3B |
Strides Pharma Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 1.5B | 1.5B | 2.6B | 3.1B | 2.5B | 1.5B | |
| Total Revenue | 32.5B | 30.2B | 36.9B | 38.9B | 46.2B | 24.4B | |
| Gross Profit | 18.4B | 14.4B | 20.6B | 21.7B | 26.4B | 27.8B | |
| Operating Income | 4.6B | (2.8B) | (797.0M) | 5.2B | 17.8B | 18.7B | |
| Ebit | 5.2B | (3.7B) | 2.6B | 1.6B | 6.7B | 7.0B | |
| Ebitda | 7.3B | (1.3B) | 5.0B | 3.8B | 8.6B | 9.0B | |
| Cost Of Revenue | 14.1B | 15.8B | 16.3B | 17.3B | 19.8B | 11.9B | |
| Income Before Tax | 2.8B | (6.5B) | (2.9B) | (1.2B) | 4.9B | 5.1B | |
| Net Income | 2.7B | (4.7B) | (2.3B) | (706.1M) | 35.9B | 37.7B | |
| Income Tax Expense | 316.5M | (1.8B) | (553.0M) | 315.9M | 775.2M | 813.9M | |
| Research Development | 1.1B | 893.9M | 638.7M | 663.9M | 597.5M | 856.4M | |
| Minority Interest | 373.4M | 140.4M | 97.0M | 237M | (40.6M) | (38.5M) | |
| Tax Provision | 316.5M | (1.8B) | (553.0M) | 315.9M | 775.2M | 813.9M | |
| Net Interest Income | (1.6B) | (1.8B) | (2.6B) | (3.1B) | (2.5B) | (2.6B) | |
| Interest Income | 353.0M | 11.3M | 1.3B | 296.4M | 340.9M | 386.8M |
Strides Pharma Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (4.1B) | 281.9M | (81.4M) | 307.0M | (2.2B) | (2.1B) | |
| Change In Cash | (564M) | 449.0M | 1.3B | (1.4B) | (484.6M) | (460.3M) | |
| Free Cash Flow | 1.8B | (4.0B) | (505.3M) | 5.8B | 4.4B | 4.6B | |
| Depreciation | 2.1B | 2.3B | 2.4B | 2.2B | 1.9B | 1.4B | |
| Other Non Cash Items | 1.7B | 3.5B | 5.3B | 6.2B | (28.3B) | (26.9B) | |
| Dividends Paid | 1.5B | 179.2M | 224.3M | 135.2M | 229.9M | 218.4M | |
| Capital Expenditures | 3.0B | 1.4B | 949.4M | 1.2B | 2.4B | 3.8B | |
| Net Income | 2.9B | (6.5B) | (2.7B) | (627.2M) | 35.9B | 37.7B | |
| End Period Cash Flow | 1.3B | 1.7B | 3.0B | 1.6B | 1.1B | 1.1B | |
| Investments | (2.4B) | 1.4B | 3.0B | (1.5B) | (896.9M) | (852.0M) | |
| Net Borrowings | 4.1B | (13.8B) | 1.4B | 5.9B | 5.3B | 5.6B | |
| Change To Netincome | (1.1B) | 3.1B | 3.3B | 1.6B | 1.8B | 1.9B |
Strides Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Strides Pharma's current stock value. Our valuation model uses many indicators to compare Strides Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Strides Pharma competition to find correlations between indicators driving Strides Pharma's intrinsic value. More Info.Strides Pharma Science is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.36 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Strides Pharma Science is roughly 2.74 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Strides Pharma's earnings, one of the primary drivers of an investment's value.Strides Pharma Science Systematic Risk
Strides Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Strides Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Strides Pharma Science correlated with the market. If Beta is less than 0 Strides Pharma generally moves in the opposite direction as compared to the market. If Strides Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Strides Pharma Science is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Strides Pharma is generally in the same direction as the market. If Beta > 1 Strides Pharma moves generally in the same direction as, but more than the movement of the benchmark.
Strides Pharma Science Total Assets Over Time
Strides Pharma July 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Strides Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Strides Pharma Science. We use our internally-developed statistical techniques to arrive at the intrinsic value of Strides Pharma Science based on widely used predictive technical indicators. In general, we focus on analyzing Strides Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Strides Pharma's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.01 | |||
| Information Ratio | 0.1344 | |||
| Maximum Drawdown | 13.04 | |||
| Value At Risk | (3.31) | |||
| Potential Upside | 5.67 |
Additional Tools for Strides Stock Analysis
When running Strides Pharma's price analysis, check to measure Strides Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Strides Pharma is operating at the current time. Most of Strides Pharma's value examination focuses on studying past and present price action to predict the probability of Strides Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Strides Pharma's price. Additionally, you may evaluate how the addition of Strides Pharma to your portfolios can decrease your overall portfolio volatility.